Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 11Neoplasm Metastasis 3Lung Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Thymoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Gastroesophageal Cancer 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Clinical Stage IVB Gastric Cancer AJCC v8 1Clinical Stage III Gastric Cancer AJCC v8 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Brain Neoplasms 1

Interventions

camrelizumab 2apatinib 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Ramucirumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Gastric Adenocarcinoma × Ramucirumab × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡